X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (311) 311
alemtuzumab (255) 255
campath-1h (231) 231
index medicus (179) 179
transplantation (170) 170
male (167) 167
antibodies, monoclonal, humanized (161) 161
female (148) 148
middle aged (142) 142
antibodies, monoclonal - therapeutic use (131) 131
adult (129) 129
antibodies, neoplasm - therapeutic use (109) 109
surgery (108) 108
hematology (95) 95
treatment outcome (91) 91
immunology (89) 89
alemtuzumab campath-1h (86) 86
therapy (83) 83
immunosuppressive agents - therapeutic use (82) 82
aged (79) 79
oncology (76) 76
immunosuppression (63) 63
monoclonal antibodies (59) 59
antineoplastic agents - therapeutic use (57) 57
leukemia, lymphocytic, chronic, b-cell - drug therapy (55) 55
renal-transplantation (53) 53
kidney transplantation (52) 52
rituximab (49) 49
graft rejection - prevention & control (46) 46
antibodies, monoclonal - administration & dosage (45) 45
adolescent (44) 44
fludarabine (44) 44
kidney-transplantation (44) 44
remission induction (44) 44
antibodies, monoclonal - adverse effects (42) 42
antibodies, neoplasm - administration & dosage (42) 42
immunotherapy (42) 42
induction (42) 42
cd52 antigen (41) 41
recipients (41) 41
kidney transplantation - immunology (40) 40
monoclonal-antibody (40) 40
antibodies, monoclonal, humanized - therapeutic use (39) 39
antibodies, neoplasm - adverse effects (39) 39
chronic lymphocytic-leukemia (38) 38
retrospective studies (38) 38
tacrolimus (38) 38
follow-up studies (36) 36
tolerance (36) 36
care and treatment (35) 35
chronic lymphocytic leukemia (35) 35
graft rejection - immunology (34) 34
kidneys (34) 34
health aspects (33) 33
t cells (31) 31
campath‐1h (30) 30
animals (29) 29
cd52 (29) 29
lymphocytes (29) 29
rejection (29) 29
risk factors (29) 29
child (28) 28
graft survival (28) 28
time factors (28) 28
transplantation, homologous (28) 28
phase-ii trial (27) 27
young adult (27) 27
lymphocyte depletion (26) 26
organ-transplantation (26) 26
antibodies, neoplasm - pharmacology (25) 25
cancer (25) 25
disease (25) 25
drug therapy (25) 25
leukemia (25) 25
monotherapy (25) 25
research (25) 25
tacrolimus - therapeutic use (25) 25
analysis (24) 24
antibodies, monoclonal - pharmacology (24) 24
article (24) 24
clinical trials as topic (24) 24
antibody (23) 23
antigens, cd - immunology (23) 23
drug therapy, combination (23) 23
graft rejection (23) 23
survival analysis (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
campath-1h induction (22) 22
cll (22) 22
immunosuppressive agents - administration & dosage (22) 22
immunosuppressive agents - adverse effects (22) 22
randomized-trial (22) 22
tacrolimus monotherapy (22) 22
acute rejection (21) 21
antibodies (21) 21
flow cytometry (21) 21
leukemia, lymphocytic, chronic, b-cell - therapy (21) 21
trial (21) 21
mycophenolate-mofetil (20) 20
survival (20) 20
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 06/2013, Volume 119, Issue 12, pp. 2258 - 2267
BACKGROUND Scarce systematic trial data have prevented uniform therapeutic guidelines for T‐cell prolymphocytic leukemia (T‐PLL). A central need in this... 
T‐cell prolymphocytic leukemia | T‐cell leukemia 1 | mature T‐cell leukemia/lymphoma | alemtuzumab, fludarabine, mitoxantrone, and cyclophosphamide chemotherapy | T-cell leukemia 1 | T-cell prolymphocytic leukemia | mature T-cell leukemia/lymphoma | mitoxantrone | and cyclophosphamide chemotherapy | CAMPATH-1H | DIAGNOSIS | PENTOSTATIN | CARDIAC TOXICITY | lymphoma | COMBINATION | TRANSPLANTATION | PHASE-II TRIAL | THERAPY | alemtuzumab | ONCOLOGY | fludarabine | CHRONIC LYMPHOCYTIC-LEUKEMIA | mature T-cell leukemia | MYCOSIS FUNGOIDES/SEZARY-SYNDROME | Proto-Oncogene Proteins - metabolism | Cyclophosphamide - administration & dosage | Mitoxantrone - administration & dosage | Humans | Middle Aged | Vidarabine - adverse effects | Leukemia, Prolymphocytic, T-Cell - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Vidarabine - analogs & derivatives | Alemtuzumab | Remission Induction | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Prolymphocytic, T-Cell - drug therapy | Proto-Oncogene Proteins - analysis | Chromosome Aberrations | Adult | Female | Aged | Leukemia, Prolymphocytic, T-Cell - mortality | Vidarabine - administration & dosage | Chemotherapy, Combination | Research | Lymphocytic leukemia | Drug therapy | Patient outcomes | Methods | Index Medicus | Abridged Index Medicus
Journal Article
Transplantation, ISSN 0041-1337, 06/2014, Volume 97, Issue 11, pp. 1128 - 1138
Journal Article
Transplantation, ISSN 0041-1337, 10/2011, Volume 92, Issue 7, pp. 774 - 780
Background. Immunosuppressive regimens for kidney transplantation which reduce the long-term burden of immunosuppression are attractive, but little data are... 
Prospective | Trial | Alemtuzumab | Tacrolimus | Kidney | Transplant | SURGERY | CAMPATH-1H | RENAL-TRANSPLANTATION | MONOCLONAL-ANTIBODY | THYMOGLOBULIN | IMMUNOLOGY | PANCREAS-KIDNEY | TRANSPLANTATION | IMMUNOTHERAPY | IMMUNOSUPPRESSION | REJECTION | WITHDRAWAL | ANTITHYMOCYTE GLOBULIN INDUCTION | Antibodies, Neoplasm - therapeutic use | Graft Survival - immunology | Prospective Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Kidney Transplantation - physiology | Adult | Female | Drug Therapy, Combination | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Immunoglobulin G - therapeutic use | Treatment Outcome | Tacrolimus - adverse effects | Immunoglobulin G - adverse effects | Mycophenolic Acid - adverse effects | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Graft Survival - physiology | Immunosuppressive Agents - adverse effects | Kidney Transplantation - immunology | Longitudinal Studies | Antibodies, Neoplasm - adverse effects | Mycophenolic acid | Opportunist infection | Data processing | Survival | Immunosuppressive agents | Graft rejection | Immunosuppression | Donors | Interleukin 2 | Monoclonal antibodies | Mycophenolate mofetil | Steroid hormones | Kidney transplantation
Journal Article
Journal of Rheumatology, ISSN 0315-162X, 10/2015, Volume 42, Issue 10, pp. 1906 - 1913
Journal Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 2011, Volume 30, Issue 7, pp. 743 - 754
Journal Article
Journal Article